EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Parkinsons disease with 2- -2-Imidazoline



Treatment of Parkinsons disease with 2- -2-Imidazoline



Official Gazette of the United States Patent & Trademark Office Patents 1226(1), Sep 7




(PDF 0-2 workdays service: $29.90)

Accession: 035980564

Download citation: RISBibTeXText



Related references

I2-imidazoline receptors in patients with Parkinsons disease and Alzheimer-type dementia. Methods & Findings in Experimental & Clinical Pharmacology 19(SUPPL A): 80, 1997

Possibilities for optimizing treatment of Parkinsons disease Ninth international symposium on Parkinsons disease, June 5-9, 1988 in Jerusalem. Zhurnal Nevropatologii i Psikhiatrii Imeni S S Korsakova 92(2): 136-137, 1992

Comparison of the Unified Parkinsons Disease Rating Scale and Short Parkinsons Evaluation Scale after Levodopa loading test in Parkinsons disease. Neurology 56(8 Supplement 3): A282, April 24, 2001

Treatment of Parkinsons disease A psychotherapy in Parkinsons disease. A M A Arch Neurol Psychiat: 1-272, 1957

Patterns of neuropsychological impairment are distinct in parkinsons disease alzheimers disease and parkinsons disease dementia. Neurology 41(3 SUPPL 1): 177, 1991

I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. Drugs & Aging 17(2): 133-159, 2000

A radical basis of nigrostriatal dopamine cell death in Parkinsons disease Oxygen free radicals and Parkinsons disease. Racagni, G , Brunello, N , Langer, S Z International Academy for Biomedical and Drug Research; Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction 229-237, 1994

Self-reported functioning and well-being in patients with Parkinsons disease Comparison of the short-form health survey and the Parkinsons disease questionnaire. Age & Ageing 24(6): 505-509, 1995

Etiology of parkinsons disease complex i deficiency in 1 methyl 4 phenyl 1 2 3 6 tetrahydropyridine induced parkinsonism and parkinsons disease. Sato, T And S Dimauro Progress in Neuropathology, Vol 7 Mitochondrial Encephalomyopathies; Satellite Symposium Of The Xith International Congress Of Neuropathology, Tokyo, Japan, August 31-September 1, 1990 Xxi+258p Raven Press: New York, New York, Usa Illus 237-247, 1991

Enhanced binding to NMDA receptors in the striatum of Parkinsons disease, Alzheimers disease and mixed Parkinsons disease/Alzheimers disease patients. Society for Neuroscience Abstracts 19(1-3): 194, 1993

The majority of dementia patients with the pathological findings of Parkinsons disease at autopsy do not present with Parkinsonian symptoms or signs and are not treated for Parkinsons disease during their course. Neurology 48(3 SUPPL 2): A104, 1997

Studies on the chemical anatomy of the basal ganglia in parkinsons disease and in animal models of parkinsons disease. Calne, D B , Et Al Aging Series (New York), Vol 36 Parkinsonism And Aging; Symposium, Milan, Italy, November 1987 Xii+299p Raven Press: New York, New York, Usa Illus 9-24, 1989

The risk of Parkinsons disease among persons with a family history of Parkinsons disease or dementia The Rotterdam Study. Neurology 48(3 SUPPL 2): A333-A334, 1997

Epidemiologic studies of parkinsons disease part 1 smoking and parkinsons disease a survey and explanatory hypothesis. American Journal Of Epidemiology: 16-25, 1971

AltropaneTM SPECT binding ratios in Parkinsons disease, Parkinsons plus syndromes, non-Parkinsonian movement disorders, and normals, and comparison with disease severity scores. Journal of Nuclear Medicine 43(5 Supplement): 18P-19P, 2002